New company co-founded by Rice faculty member aims to move beyond symptom management in preeclampsia
Emvena Therapeutics, a biotechnology startup co-founded by Rice’s Kelsey Swingle, has launched to develop disease-modifying mRNA treatments for preeclampsia, backed by the Penn-BioNTech Innovative Therapeutics Seed Fund. The startup uses placenta-targeted lipid nanoparticles to address the root biological causes of the condition rather than just managing symptoms.
